Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Plasma beta-amyloid and duration of Alzheimer's disease in adults with Down syndrome.

International journal of geriatric psychiatry - 1 Feb 2010

Prasher V P, Sajith S G, Mehta P, Zigman W B, Schupf N

Abstract excerpt

OBJECTIVES: To investigate the relation of plasma levels of Abeta peptides (Abeta1-40 and Abeta1-42) and apolipoprotein E (APOE) genotype to dementia status, and the duration of Alzheimer's disease (AD) in adults with Down syndrome (DS). METHODS: Adults with DS were recruited from community settings and followed up for a mean period of 6.7 years. Plasma levels Abeta1-40 and Abeta1-42 and APOE genotype were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer Disease
Share to Amyloid beta-Peptides
Share to Apolipoprotein E4

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Biomarkers

Share to Dementia

Share to Down Syndrome

Share to Peptide Fragments

Share to Predictive Value of Tests

Source

Open in PubMed Open full text

Identifiers

PMID: 19513990
DOI: 10.1002/gps.2321
PMCID: PMC2811215

Genes

APOE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plasma beta-amyloid and duration of Alzheimer's disease in adults with Down syndrome.PMID 19513990Read ↗

Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome.Semantic proximity Read ↗

Cross-Sectional Exploration of Plasma Biomarkers of Alzheimer’s Disease in Down Syndrome: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) StudySemantic proximity Read ↗

Amyloid beta concentrations in older people with Down syndrome and dementia.Semantic proximity Read ↗

Plasma levels of amyloid beta 40 and 42 are independent from ApoE genotype and mental retardation in Down syndrome.Semantic proximity Read ↗

APOE genotype and gender effects on Alzheimer disease in 100 adults with Down syndrome.Semantic proximity Read ↗

Aging with Down Syndrome—Where Are We Now and Where Are We Going?Semantic proximity Read ↗

Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study.Semantic proximity Read ↗

Clinical aspects and biomarkers of Alzheimer's disease in Down syndrome.Semantic proximity Read ↗

The Alzheimer's Biomarker Consortium‐Down Syndrome: Rationale and methodologySemantic proximity Read ↗

Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s diseaseSemantic proximity Read ↗

Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional studySemantic proximity Read ↗

Down syndrome and Alzheimer's disease: A link between development and agingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.